Pharma Companies ki Q4 Earnings: Kya Hai Khabar?
Pharma sector mein kuchh badi companies ki Q4 FY25 earnings ki report aa gayi hai. Systematix ke hisab se, revenue mein kareeb 10% ka growth dekhne ko mil sakta hai, lekin domestic business mein thodi weakness bhi ho sakti hai.
US Market mein Teji ki Umeed
US mein generic Revlimid ki demand badhne se Zydus Life aur Sun Pharma ko fayda hoga. Cipla ko generic lanreotide sales mein sudhar se, aur Lupin ko flu aur antibiotics ki demand badhne se fayda ho sakta hai.
Domestic Market Ka Scene
India mein branded formulations segment mein high single-digit growth ki umeed hai. Dr. Reddy’s, Sun Pharma, Mankind, aur Ajanta Pharma, in sab companies ki growth dusri companies se zyada tezi se ho sakti hai. US market mein koi major launch toh nahi hue hain, lekin existing products ki sales badhti rahegi.
Systematix Report ki Highlight
Systematix ne pharma companies ke Q4 results ka analysis kiya hai. Unka kehna hai ki overall growth steady rahega, aur margins bhi better honge. Domestic market mein thodi seasonal weakness dekhne ko mil sakti hai, lekin US market mein growth ki umeed hai.
Expert Opinion aur Disclaimer
Yeh report external expert ki hai, aur NDTV Profit iski accuracy ke liye zimmedar nahi hai. Investment decisions lene se pehle apne financial advisor se salah zarur len.
Aage Kya?
Pharma companies ki performance kaafi had tak US market par depend karegi. Generic medicines ki demand aur pricing pressure, yeh sab important factors hain jin par nazar rakhni hogi. Indian market mein bhi, competition aur government policies ka asar dekhne ko milega.
Key Companies par Focus
Zydus Life, Sun Pharma, Cipla, Lupin, Dr. Reddy’s, Mankind, aur Ajanta Pharma, in companies ki performance aane wale time mein kaafi interesting hogi. Inki earnings reports aur management commentary se market ka future trend pata chalega.
